POINT Biopharma Ownership

Summary

PNTDelisted Stock

USD 9.06 0.10 1.09%

POINT Biopharma owns a total of 106.57 Million outstanding shares. 30% of POINT Biopharma Global outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Therefore, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Some institutional investors establish a significant position in stocks such as POINT Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of POINT Biopharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

POINT Stock Ownership Analysis

About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of POINT Biopharma was at this time reported as 4.01. The company had not issued any dividends in recent years. POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana. Point Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. To find out more about POINT Biopharma Global contact Joe McCann at 647 812 2417 or learn more at https://www.pointbiopharma.com.

POINT Biopharma Global Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific POINT Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on POINT Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases POINT Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Bvf Partners L P over six months ago Sale by Bvf Partners L P of 8974245 shares of POINT Biopharma
		Joe McCann over a year ago POINT Biopharma exotic insider transaction detected
		Bvf Partners L P over a year ago POINT Biopharma exotic insider transaction detected
		Fleshner Neil E over a year ago Bona fide gift to Fleshner Neil E of 250000 shares of POINT Biopharma subject to Section 16
		Martell Bridget A over a year ago Acquisition by Martell Bridget A of 80503 shares of POINT Biopharma subject to Rule 16b-3
		Goodman Jonathan R over a year ago Acquisition by Goodman Jonathan R of 44749 shares of POINT Biopharma subject to Rule 16b-3
		Demers William L over a year ago Acquisition by Demers William L of 131355 shares of POINT Biopharma subject to Rule 16b-3
		Hogue Gerald L over a year ago Exercise or conversion by Hogue Gerald L of 17936 shares of POINT Biopharma subject to Rule 16b-3

POINT Biopharma Outstanding Bonds

POINT Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. POINT Biopharma Global uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most POINT bonds can be classified according to their maturity, which is the date when POINT Biopharma Global has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Dana 575 percent Corp Bond US235822AB96	View
	Volcan Compania Minera Corp Bond USP98047AC08	View
	Boeing Co 2196 Corp Bond US097023DG73	View
	HSBC Holdings PLC Corp Bond US404280DR76	View
	MPLX LP 4875 Corp Bond US55336VAG59	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	International Game Technology Corp Bond US460599AD57	View
	BNP Paribas FRN Corp Bond USF1R15XK367	View

View All POINT Biopharma Corporate Bonds

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Other Consideration for investing in POINT Stock

If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.

	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC